Form 4: Arcus Biosciences CFO Sells Shares Under 10b5-1 Plan

Arcus Biosciences' Chief Financial Officer, Robert C. Goeltz II, sold 5,000 shares of common stock for $20 per share as part of a pre-arranged trading plan.

Summary

• Robert C. Goeltz II, Chief Financial Officer of Arcus Biosciences, Inc. (RCUS), reported a sale of common stock.
• The transaction involved the disposition of 5,000 shares of common stock.
• The shares were sold at a price of $20 per share.
• Following this transaction, Mr. Goeltz II directly beneficially owns 92,138 shares of Arcus Biosciences common stock.
• The sale was executed on October 28, 2025.
• This transaction was made pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Goeltz II on March 7, 2023.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale executed under a pre-arranged Rule 10b5-1 trading plan, which typically does not carry significant positive or negative implications for the company's outlook.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and non-discretionary transaction rather than a reaction to new material non-public information.

Negatives

• A reduction in direct beneficial ownership by a key executive, though planned, represents a decrease in insider holdings.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common across all industries, including biotechnology. These pre-arranged plans allow insiders to sell shares systematically without being accused of trading on material non-public information. This specific transaction by Arcus Biosciences' CFO is a routine disclosure and does not inherently signal any specific industry trend or competitive development.

Comparison to Industry Standards

• This transaction is a standard insider sale under a Rule 10b5-1 plan, which is a common practice among executives in publicly traded companies across various sectors, including biotech.
• There are no specific comparable companies, projects, or results mentioned in this filing to assess against industry benchmarks.
• The sale amount of 5,000 shares for $100,000 is a relatively small percentage of the CFO's total holdings (92,138 shares remaining), which is typical for routine liquidity or diversification purposes rather than a significant change in conviction.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but generally viewed as routine given the 10b5-1 plan. Unlikely to significantly impact shareholder sentiment.
• Employees, Customers, Suppliers, Creditors: No direct impact from this insider transaction.

Next Steps

• The filing does not specify any future actions, events, or milestones for the company or the reporting person beyond the reported transaction.

Key Dates

Recommendation

The reported transaction is a routine insider sale by the Chief Financial Officer, executed under a pre-arranged Rule 10b5-1 trading plan. Such planned sales are common for executive compensation and diversification purposes and do not typically signal a change in the company's fundamental prospects or management's confidence. Therefore, this filing alone does not provide a basis for a change in investment recommendation, and a 'hold' stance is maintained.

Keywords

Arcus Biosciences, RCUS, Insider Trading, Form 4, Robert C. Goeltz II, Chief Financial Officer, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals